Roles of Gag and NCp7 in Facilitating trna 3 Lys Annealing to Viral RNA in Human Immunodeficiency Virus Type 1

Transcription

1 JOURNAL OF VIROLOGY, Aug. 2009, p Vol. 83, No X/09/$ doi: /jvi Copyright 2009, American Society for Microbiology. All Rights Reserved. Roles of Gag and NCp7 in Facilitating trna 3 Annealing to Viral RNA in Human Immunodeficiency Virus Type 1 Fei Guo, 1,4 * Jenan Saadatmand, 1,2 Meijuan Niu, 1 and Lawrence Kleiman 1,2,3 * Lady Davis Institute for Medical Research and McGill AIDS Centre, Jewish General Hospital, 1 and Departments of Medicine 2 and Microbiology and Immunology, McGill University, 3 Montreal, H3T 1E2 Quebec, Canada, and State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing , People s Republic of China 4 Received 9 March 2009/Accepted 26 May 2009 In protease-negative human immunodeficiency virus type 1 (HIV-1) [Pr( )], the amount of trna 3 annealed by Gag is modestly reduced ( 25%) compared to that annealed by mature nucleocapsid (NCp7) in proteasepositive HIV-1 [Pr( )]. However, the trna 3 annealed by Gag also has a strongly reduced ability to initiate reverse transcription and binds less tightly to viral RNA. Both in vivo and in vitro, APOBEC3G (A3G) inhibits trna 3 annealing facilitated by NCp7 but not annealing facilitated by Gag. While transient exposure of Pr( ) viral RNA to NCp7 in vitro returns the quality and quantity of trna 3 annealing to Pr( ) levels, the presence of A3G both prevents this rescue and creates a further reduction in trna 3 annealing. Since A3G inhibition of NCp7-facilitated trna 3 annealing in vitro requires the presence of A3G during the annealing process, these results suggest that in Pr( ) viruses NCp7 can displace Gag-annealed trna 3 and re-anneal it to viral RNA, the re-annealing step being subject to A3G inhibition. This supports the possibility that the initial annealing of trna 3 in wild-type, Pr( ) virus may be by Gag and not by NCp7, perhaps offering the advantage of Gag s preference for binding to RNA stem-loops in the 5 region of viral RNA near the trna 3 annealing region. * Corresponding author. Mailing address for Lawrence Kleiman: Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote St. Catherine Rd., Montreal, Quebec, Canada H3T 1E2. Phone: (514) Fax: (514) Mailing address for Fei Guo: State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing , People s Republic of China. Phone: Fax: guoafei@gmail.ca. Published ahead of print on 3 June In human immunodeficiency virus type 1 (HIV-1), minusstrand viral DNA synthesis by reverse transcriptase (RT) is initiated by a cellular trna, trna 3, which binds to sequences in the 5 region of the viral RNA genome (33). These sequences include the primer binding site (PBS), an 18-nucleotide (nt) sequence complementary to the 3 -terminal 18 nt of trna 3, and an 8-nt sequence upstream of the PBS, known as the primer activation signal, that is complementary to the 5 portion of the T C arm in trna 3 (3, 4). It has been shown that primer trna annealing occurs independently of precursor processing in HIV-1 (30), murine retrovirus (14), and avian retrovirus (45). Annealing of trna 3 to viral RNA is facilitated by nucleocapsid protein. Both the mature nucleocapsid (NCp7) and nucleocapsid sequences within the precursor Gag protein facilitate annealing (11). HIV-1 nucleocapsid has two zinc fingers. The basic amino acids flanking the N-terminal zinc finger are required for trna 3 annealing, but the two zinc fingers appear to have less effect (10, 15, 24, 34). The role of nucleocapsid in the annealing process has been predicted to be twofold (23). One role is to facilitate a nucleation step that brings trna 3 and the largely, if not entirely (depending on the RNA model used), singlestranded PBS sequences together, which is probably facilitated primarily by the basic amino acids flanking the first zinc finger. Other roles, which may be facilitated by the zinc fingers, may be to both denature double-stranded RNA regions in viral RNA involved in annealing (such as the primer activation signal), and/or alter RNA conformation to make such regions more available for annealing. Smaller effects on the rate of annealing by mutated zinc fingers may be explained by the fact that, while the mutant NCp7 is a weaker duplex destabilizer, it is a better duplex nucleating agent, and the two phenomenon may balance each other (23). NCp7 has also been predicted to play a role in blocking the interaction between the T C and D loops of trna 3, thereby facilitating a destabilization of tertiary structure which might also promote annealing (24, 46). Earlier studies have indicated that in protease-negative (Pr( )) HIV-1, Gag is sufficient for annealing trna 3 to the viral RNA (10, 16). However, the placement of trna 3 on viral RNA is not optimal, since the incorporation of the first deoxynucleoside triphosphate (dntp), dctp, was reduced by 70% in an in vitro reverse transcription system consisting of total viral RNA as the source of the primer trna 3 /viral RNA template, exogenous HIV-1 RT, and a suboptimal concentration of dctp that did not allow for complete incorporation of dctp (11). In the present study, we provide further evidence for a weaker binding of trna 3 annealed to viral RNA by Gag rather than by NCp7, by showing that trna 3 annealed by Gag is more readily displaced from the PBS by reverse transcription initiated from a DNA primer downstream of the PBS. We have also used here the ability of the antiviral protein APOBEC3G (A3G) to inhibit trna 3 annealing in HIV-1 (20, 21) to deduce the roles of Gag and NCp7 in the annealing process in Pr( )Vif( ) viruses. HIV-1 produced from cells 8099

2 8100 GUO ET AL. J. VIROL. expressing human APOBEC3G (A3G), also known as nonpermissive cells, has a severely reduced ability to productively infect other cells. A3G is incorporated into Vif-negative HIV-1 that are either protease-positive [Pr( )] or Pr( ) (9), and its incorporation depends upon the interaction of A3G with nucleocapsid sequences in Gag (1, 9, 38, 44, 49). The presence of the HIV-1 protein Vif greatly inhibits this incorporation due to a cytoplasmic interaction with A3G that results in A3G s degradation via proteasomes (48). New infections by HIV-1 containing A3G are accompanied by a reduced production of viral DNA transcripts (19, 36, 39, 41). Although it has been suggested that cytidine deamination by A3G of newly synthesized DNA results in this DNA s degradation (25, 35, 40, 52), other reports have indicated that the reduced viral DNA production is due to a direct inhibition of reverse transcription, occurring at both the initiation stage of reverse transcription (20, 21) and at the first and/or second DNA strand transfer stages (37, 42). We have provided evidence that the reduction in the initiation of reverse transcription is associated with an inhibition of trna 3 annealing to the viral RNA genome by A3G (20, 21). This inhibition of annealing by A3G has been reported in naturally nonpermissive cells, such as H9 and MT2 (20), and in permissive cells that express exogenous A3G (293T cells) (20). A3G has also been reported to inhibit the NCp7-facilitated annealing of trna 3 in vitro (21). In the latter report, we showed that (i) the in vitro inhibition of trna 3 annealing by A3G is dependent upon an interaction occurring between NCp7 and A3G and (ii) that A3G, once annealed by NCp7, cannot alter annealing, i.e., A3G must be present during the annealing process in order to inhibit it. In the present study, we also show, using Pr( )Vif( ) and Pr( )Vif( ) virions, that the ability of A3G to inhibit annealing and initiation of reverse transcription only applies to trna 3 annealed by NCp7 and not to trna 3 annealed by Gag, and we use this property of A3G to examine the temporal roles of Gag and NCp7 in promoting trna 3 annealing in Pr( )Vif( ) virions. MATERIALS AND METHODS Plasmid construction. BH10 is a simian virus 40-based vector that contains full-length wild-type BH10 strain of HIV-1 proviral DNA, while BH10P contains an inactive viral protease (D25G). The constructions of BH10.Vif [(Pr( )Vif( )] and BH10P Vif [Pr( )Vif( )] were done by introducing into BH10 and BH10P a stop codon right after the start codon (ATG) of the Vif reading frame at nt 5043by using a site-directed mutagenesis kit (Stratagene) and the primer pair 5 -AGATCATTAGGGATTTAGGAAAACAGATGGCAG-3 and 5 -CTGCCATCTGTTTTCCTAAATCCCTAATGATCT-3. The human papobec3g was constructed as previously described (9) and expresses wildtype human APOBEC3G with a fused hemagglutinin (HA) tag at the C terminus. Protein production. Human A3G was obtained from Diagnostics, Inc. It was produced in baculovirus and was purified by (NH 4 ) 2 SO 4 fractionation and immunoaffinity chromatography to 95% purity. HIV-1 RT, purified from bacteria as previously described (29), was a gift from Matthias Gotte (McGill University). Recombinant wild-type NCp7 was a gift from R. Gorelick and was prepared as previously described (8, 22), including purification by reversed-phase high-pressure liquid chromatography after the protein was denatured in 8 M guanidine hydrochloride. Gag p6 was a gift from A. Rein and was prepared as previously described (11). Gag p6 was used because it is easier to purify than full-length Gag, its assembly properties in vitro have been characterized (7), and it can efficiently facilitate the annealing of trna 3 to viral RNA (16). Cells, transfections, and virus purification. HEK-293T cells were grown in complete Dulbecco modified Eagle medium plus 10% fetal calf serum, 100 U of penicillin, and 100 g of streptomycin/ml. For the production of viruses, HEK- 293T cells were transfected by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer s instructions. Supernatant was collected at 48 h posttransfection. Viruses were pelleted from culture medium by centrifugation in a Beckman Ti-45 rotor at 35,000 rpm for 1 h. The viral pellets were then purified by 15% sucrose onto a 65% sucrose cushion. The band of purified virus was removed and pelleted in 1 TNE (20 mm Tris [ph 7.8], 100 mm NaCl, 1 mm EDTA) in a Beckman Ti-45 rotor at 40,000 rpm for 1 h. Viral RNA isolation and quantitation. Total viral RNA was extracted from viral pellets by using the guanidinium isothiocyanate procedure as previously described (28) and was dissolved in 5 mm Tris buffer (ph 7.5). As described in an earlier study (11), hybridization to dot blots of total viral RNA were carried out with 5-32 P-end-labeled DNA probes complementary to either the 3 -terminal 18 nt of trna 3 (5 -TGGCGCCCGAACAGGGAC-3 ) ortothe5 end of the HIV-1 genomic RNA, just upstream of the PBS (5 -CTGACGCTCTCGCA CCC-3 ). trna 3 -primed initiation of reverse transcription. Total viral RNA isolated from virus produced in transfected 293T cells was used as the source of a primer trna annealed to viral RNA in an in vitro reverse transcription reaction as previously described (29). Briefly, total viral RNA was incubated at 37 C for 15 min in 20 l of RT buffer (50 mm Tris-HCl [ph 7.5], 60 mm KCl, 3 mm MgCl 2, 10 mm dithiothreitol [DTT]) containing 50 ng of purified HIV RT, 10 U of RNasin, and various dntps. To measure the ability of annealed trna 3 to be extended by six deoxyribonucleotides, the RT reaction mixture contained 200 M dctp, 200 M dttp, 5 Ci of [ - 32 P]dGTP (0.16 M), and 50 M ddatp. The reaction conditions for the 6-nt extension assay were established previously (11), and the reactions contained all of the reagents, including dntps, in excess, so that the amount of dntp extension is proportional to the amount of trna 3 annealed to the viral RNA. In that same study, we also prepared a dose curve using increasing amounts of dctp, and measured the amount of trna 3 extended only by the first dntp, dctp. We found that at lower concentrations of dctp the amount of trna 3 extended is determined by the dctp concentration and not by the amount of trna 3 annealed to the viral RNA. At such suboptimal concentrations of dctp (i.e., 0.16 M), equal amounts of trna 3 annealed by Gag or NCp7 (determined by the 6-nt extension) produce very different amounts 1 extensions, which we have interpreted as reflecting different annealing conformations that reflect different efficiencies for the anneale trna 3 in capturing this first dntp. Thus, to measure the ability of annealed trna 3 to be extended by one deoxyribonucleotide, the RT reaction mixture contained only 0.16 M [ - 32 P]dCTP. Reaction products were resolved by using one-dimensional (1D) 6% polyacrylamide gel electrophoresis (PAGE) containing 7 M urea (29). Transient exposure of viral RNA from BH10 or BH10P to A3G in the presence of either bovine serum albumin (BSA), NCp7, or Gag p6. Total viral RNA from BH10 or BH10P was transiently exposed for 30 min at 37 C to A3G in the presence of 10 pmol of either BSA, NCp7, or Gag p6. Deproteinization was performed through the addition of 1 ml of proteinase K (5 mg/ml) to the reactions, which were incubated at 37 C for 30 min, followed by phenol-chloroform extraction to remove both proteinase K and digested residual proteins. The viral RNA complex was ethanol precipitated, dried, and used in the 6 RT reaction. trna 3 occupation of the PBS. A 28-nt DNA oligomer (5 -CCCCGCTTAA TACTG ACGCTCTCGCACC-3 ) was 5 end labeled with 32 P using T4 kinase and was complementary to sequences in HIV-1 RNA genome 139 bases downstream of the PBS. The complex was then incubated at 37 C for 30 min in 20 l of RT buffer (50 mm Tris-HCl [ph 7.5], 60 mm KCl, 3 mm MgCl 2, 10 mm DTT) containing 50 ng of HIV RT, 10 U of RNasin, 200 M concentrations of dntps, and reaction products, including full-length (365 nt) and truncated (167 nt, due to occupation of the PBS by trna 3 ) products, were resolved by using 1D 6% PAGE with gels containing 7 M urea. In vitro annealing of trna 3 to viral RNA. Human placental trna 3 was hybridized with synthetic HIV-1 viral genomic RNA. The trna 3 was purified from human placenta as previously described (32), using standard chromatography procedures (sequentially DEAE-Sephadex A-50, reversed-phase chromatography [RPC-5], and Porex C4) and, finally, 2D PAGE. The synthetic genomic RNA (497 bases), comprising the complete R and U5 regions, the PBS, leader, and part of the gag coding region, was synthesized as previously described (29) from the AccI-linearized plasmid phiv-pbs (2) with the MEGAscript transcription system (Ambion, Inc.). For heat annealing of trna 3, 1 pmol of trna 3 was combined with 1 pmol of synthetic HIV-1 RNA template in a solution containing 50 mm Tris-HCl (ph 7.5), 60 mm KCl, 3 mm MgCl 2, 10 mm DTT, and 10 U of RNasin. The annealing reaction mixture was heated sequentially at 85 C for 5 min, at 50 C for 10 min, and then at 37 C for 15 min.

3 VOL. 83, 2009 Gag AND MATURE NUCLEOCAPSID IN trna ANNEALING IN HIV trna 3 annealing to viral RNA was facilitated by the addition of either NCp7 or Gag p6 as previously described (11). In order to have trna 3 annealing sensitive to regulation by NCp7, Gag p6, or A3G, in vitro conditions were used that did not maximize annealing. We have previously shown that initiation of reverse transcription ( 6-nt extension) increases linearly when 1 pmol of trna 3 is annealed to 1 pmol of synthetic HIV-1 RNA using from 30 to 60 pmol of NCp7 (21). We therefore used 30 pmol in the in vitro annealing system, which was also determined in that study (21) to result in 47% occupancy of the PBS. In that earlier study, we also noted that the maximum inhibition of the initiation of reverse transcription occurs at an A3G:NCp7 ratio of 1:30, so we used 1 pmol of A3G in the annealing reaction for our inhibition studies. Thus, 1 pmol of trna 3 was annealed to 1 pmol of synthetic HIV-1 RNA template by incubating these reagents at 37 C for 90 min with 30 pmol of NCp7 or Gag p6 in a 10- l reaction mixture containing (50 mm Tris-HCl [ph 7.2], 50 mm KCl, 5 mm MgCl 2, 10 mm DTT) and 10 U of RNasin. To study the effect of A3G on these annealing reactions, 1 pmol of either purified A3G or control BSA, dissolved in 20 mm Tris-HCl (ph 7.5), 0.1 M NaCl, and 0.01% sarcosyl, was added to the annealing reactions at the start. After the annealing and in preparation for the trna 3 priming reaction ( 1- or 6-nt extension), the trna 3 /viral RNA complex was deproteinized by the addition of 1 l of proteinase K (5 mg/ml) and was incubated at 37 C for 30 min, followed by phenolchloroform extraction to remove both proteinase K and digested residual proteins and ethanol precipitation of the viral RNA complex. To directly measure the amount of trna 3 annealed, we used an electrophoretic mobility shift assay. trna 3 was 3 end labeled with 32 pcp, as previously described (6). After deproteinization of the annealed complex with proteinase K, the free trna 3 was resolved from primer complexed with viral RNA using 1D 6% native polyacrylamide gel electrophoresis (PAGE). RESULTS A3G inhibits the initiation of reverse transcription in Pr( )Vif( ) virions but not in Pr( )Vif( ) virions. In the present study, Vif-negative HIV-1 were used to allow for the incorporation of A3G into the viruses. 293T cells were cotransfected with a plasmid coding for either Pr( )Vif( ) or Pr( )Vif( ) HIV-1, and a plasmid coding for, or not coding for, A3G. We have previously reported that we needed to produce 10-fold more A3G in 293T cells to achieve the same amount of inhibition of trna 3 annealing as achieved in nonpermissive cells such as H9 or MT2 cells (20). We interpreted this to mean that A3G expression in 293T cells is not enough to make the cell nonpermissive, and there are probably other unknown factors involved to achieve the same inhibition of annealing found in H9 or MT2 cells at lower A3G concentrations. Also, in spite of a recent report that the presence of Vif can influence the in vitro annealing of trna 3 (26), this is at odds with what we have previously reported, i.e., that the absence of Vif has no effect upon trna 3 incorporation or initiation of reverse transcription in virions produced from permissive 293T cells (20). Total viral RNA was isolated from each of the four types of viruses, and the content of viral genomic RNA and trna 3 in the total viral RNA was determined by hybridizing dot blots of the RNA with 5-32 P-endlabeled DNA probes complementary to either the 3 -terminal 18 nt of trna 3 or the 5 end of the HIV-1 genomic RNA, upstream of the PBS. Figure 1A shows that all four types of virions have equal trna 3 /viral RNA ratios, suggesting that trna 3 incorporation is not affected either by the inability to process viral proteins or by the presence of A3G in the cell and virus. Initiation of reverse transcription was measured in an in vitro reverse transcription assay that extends the trna 3 by 6 nt, using total viral RNA as the source of primer trna 3 annealed to viral RNA (see the diagram in Fig. 1B). Reaction products were resolved by using 6% 1D PAGE containing 7 M urea. Figure 1C shows the 1D PAGE pattern of the 6-ntextended trna 3 produced from the RNA isolated from each viral type, with the relative initiation normalized to Pr( )Vif( ) listed below each lane. As previously reported (11), 6-nt extension of trna 3 in Pr( )Vif( ) viruses is reduced ca. 23% from that found for Pr( )Vif( ) viruses. Also, in PR( )Vif( ) virions the presence of A3G reduces the relative initiation of reverse transcription to 40% of that obtained in the absence of A3G. However, A3G has no further effect on initiation in PR( )Vif( ) viruses. As we have previously reported (11), the 6-nt extension assay contains an excess of dntps, which hides more subtle differences in the ability of trna 3 to initiate reverse transcription when annealing of the trna 3 has occurred in either a Pr( )Vif( ) orapr( )Vif( ) environment. Such differences can be detected when the first dntp incorporated, dctp, is present at suboptimal quantities in the reverse transcription assay. This is shown in Fig. 1D, in which the initiation of reverse transcription is measured by using total viral RNA as the source of primer or template, and which occurs in the presence of only one dntp, 0.16 M [ - 32 P]dCTP. The ability of Pr( )Vif( ) viruses to incorporate dctp is reduced to less than 20% of that found for viral RNA from Pr( )Vif( ) viruses, independently of the presence of A3G. We also show that the presence of A3G in Pr( )Vif( ) viruses reduces the 1 extension to 27% of that found for Pr( )Vif( ) virions not containing A3G, an even larger reduction than we report for the 6-nt extension assay (Fig. 1C). As also seen for 6-nt extension (Fig. 1C), A3G shows no effect upon 1-nt extension in Pr( )Vif( ) virions. The effect of lack of viral protein processing and/or A3G upon the occupancy of the primer binding site by trna 3. Differences in the ability of RNA from these different viruses to extend trna 3 by 6 nt may reflect similar differences in the amount of trna 3 annealed in vivo. To further investigate this, we have used another assay that more directly measures trna 3 annealing by determining the fraction of PBSs occupied by trna 3. A diagram of the experimental strategy is shown in Fig. 2A. A 5-32 P-end-labeled DNA primer (28 nt) is annealed to a sequence in total viral RNA 139 nt downstream of the PBS and is then extended with HIV-1 RT. Full-length extension will give a labeled 365-nt product but trna 3 annealed at the PBS will block extension, resulting in a 167-nt product. Resolution of these products by 1D PAGE is shown in Fig. 2B. In addition to the 167-nt blocked product and the 365-nt full-length extension product, run-through products not reaching full length are also seen, and the major ones a, b, and c (marked with arrows in the figure) have been included in the calculation, i.e., the percentage of the PBSs that are occupied is equal to the 167-nt product/the 167-nt the 365- nt the a b c nucleotide products. This value is listed below each lane. The first two lanes show that the PBS occupancy by trna 3 in Pr( )Vif( ) is reduced from 67% occupancy to 26% occupancy when A3G is present, i.e., A3G reduces annealing by 62%. This number is very similar to the 60% reduction in initiation measured using the trna 3 6-nt extension assay (Fig. 1C), demonstrating that changes in trna 3 initiation of reverse transcription under conditions of excess dntps reflect changes in the amount of trna 3 annealed to the PBS.

4 8102 GUO ET AL. J. VIROL. FIG. 1. trna 3 incorporation and initiation of reverse transcription in Pr( )Vif( ) and Pr( )Vif( ) HIV-1, lacking or containing A3G. Four types of virions were produced from 293T cells cotransfected with a plasmid coding for Pr( )Vif( ) orpr( )Vif( ) and a plasmid coding or not coding for A3G. Total viral RNA was isolated. (A) trna 3 /viral genomic RNA ratios in virions, as determined by dot blot hybridization of total viral RNA with a probe specific for either viral RNA or trna 3. The values were normalized to that obtained for Pr( )Vif( ) produced in the absence of A3G. (B to D) Relative initiation of reverse transcription. (B) Diagram of the trna 3 /genomic RNA complex, with the 6-nt extension produced by RT underlined. (C) Six-nucleotide extension of trna 3. Total viral RNA was used as the source of primer or template in an in vitro reverse transcription system, as described in the text. In the reaction mix, dgtp is labeled, and datp is replaced with ddatp. Shown are the resolution by 1D PAGE of the 6-nt extension products of trna 3 and the quantitation, listed under each lane, of the amount of 6-nt extension per equal amount of genomic RNA, relative to that obtained for Pr( )Vif( ). (D) One-nucleotide (dctp) extension of trna 3. Total viral RNA was used as the source of primer or template in an in vitro reverse transcription system, as described in the text, whose only dntp is labeled dctp, present at suboptimal concentrations (0.16 M), as previously determined (11). Shown are the resolution by 1D PAGE of the 1-nt extension products of trna 3, and the quantitation, listed under each lane, of the amount of 1-nt extension per equal amount of genomic RNA, relative to that obtained for Pr( )Vif( ). Experiments were performed twice. The value of 67% occupancy of the PBS achieved in the absence of A3G may be considered a minimum value since we do not know if the block to elongation by trna 3 annealed to the PBS is 100% efficient. On the other hand, since we have previously shown in an in vitro trna 3 annealing system that PBS occupancy is only 1% when trna 3 is absent in a system containing both synthetic viral RNA and NCp7 (21), it is not likely that an unoccupied PBS is in a configuration that can partially block RT elongation. PBS run-through bands a, b, and c are also seen in the in vitro system with no trna 3 present (21), suggesting that these bands are due to natural pause sites of DNA synthesis that occur independently of PBS occupancy. The 6-nt extension data seen in Fig. 1C suggest that the amount of trna 3 annealed to viral RNA isolated from Pr( )Vif( ) viruses is 77% that of the value found in Pr( )Vif( ) virions, and that the much lower 1-nt extension (18% that of the value found in Pr( )Vif( ) virions (Fig. 1D) may therefore be due to a nonoptimal placement of the annealed trna 3 on the viral RNA that lessens its ability to incorporate the first nucleotide. This proposed weaker binding of trna 3 to viral RNA in Pr( )Vif( ) viruses is also supported by measurements of PBS occupancy in Pr( )Vif( ) viruses. For while the amount of annealed trna 3 may only be reduced 23% in Pr( )Vif( ) virions, the amount annealed as measured by the PBS occupancy assay is reduced 75%, suggesting that the trna 3 annealed in Pr( )Vif( ) virions is more readily displaced by the extension from the downstream DNA primer than is annealed trna 3 in Pr( )Vif( ) virions. This reduction in occupancy is not influenced by the presence or absence of A3G. Effect of A3G upon the in vitro annealing of trna 3 to viral RNA that is facilitated by either Gag p6 or NCp7. Although we have previously shown that A3G does not affect the viral production of Pr( )Vif( ) or its RNA content (20), it is technically difficult to determine whether either the production of virions or the RNA content/virus has been altered between Pr( )Vif( ) and Pr( )Vif( ), because of the different sensitivity of capsid and Gag to anti-p24. We have therefore studied the effect of A3G upon trna 3 annealed by either NCp7 or Gag in vitro, where viral production and genomic RNA is not an issue. The results obtained above using viral RNA isolated from Pr( )Vif( ) and Pr( )Vif( ) virions also assume that the key difference in trna 3 annealing and its susceptibility to inhibition by A3G in the two viral types depends upon whether Gag or NCp7 is used for annealing. To test this assumption, we performed similar studies in vitro, where trna 3 is annealed to synthetic viral RNA using either Gag p6 or NCp7, in the presence or absence of A3G. As described in detail in Mate-

5 VOL. 83, 2009 Gag AND MATURE NUCLEOCAPSID IN trna ANNEALING IN HIV FIG. 2. Measurements of the occupancy of the PBS by trna 3 in Pr( )Vif( ) and Pr( )Vif( ) HIV-1, lacking or containing A3G. Total viral RNA samples isolated from the four virus types listed in Fig. 1 were used to determine PBS occupancy by trna 3. (A) Diagram showing the strategy used to measure the percentage of the PBSs occupied with trna 3.A5-32 P-end-labeled DNA primer (28 nt) was annealed 139 bases downstream of the PBS in viral RNA and extended with reverse transcription. The full-length extension product is 365 nt, while a truncated product, resulting from blocked extension by the presence of trna 3 on the PBS, is 167 nt. (B) Separation of the full-length and truncated extension products by 1D PAGE. The ratio of truncated product to truncated, full-length product and fragments (a b c) 100 is equal to the percentage of PBSs occupied by trna 3, and these values are indicated at the bottom of each lane. Occupancy assays were repeated three times. rials and Methods, the in vitro conditions for annealing produced intermediate amounts of trna 3 annealing, in order to ensure sensitivity to differences in annealing obtained when annealing with Gag p6 or NCp7 in the presence or absence of A3G. In Fig. 3A, the 6-nt RT extension products of trna 3 are resolved by using 6% 1D PAGE containing 7 M urea. Normalizing values to that obtained for the 6-nt extension from trna 3 annealed by NCp7 in the absence of A3G, we see that 6-nt extension from trna 3 annealed by Gag p6 is ca. 70% of that achieved by NCp7-facilitated annealing. The presence of A3G in the NCp7 annealing mixture reduces 6-nt extension to ca. 18% but has no effect upon initiation when added to a Gag p6 annealing mixture. These results are similar to those obtained in Fig. 1C using RNA isolated from Pr( )Vif( ) and Pr( )Vif( ) virions, in the presence or absence of A3G, although the inhibition of NCp7-facilitated annealing by A3G is greater in vitro (82% reduction) than in vivo (60% reduction). The fact that A3G can inhibit trna 3 annealing with a 30-fold molecular excess of NCp7 and that inhibition of annealing requires an interaction of A3G with NCp7 (21) suggests that that A3G shows a preference for binding to NCp7 involved in trna 3 annealing, which might explain how only a limited number of A3G molecules in the virus can still cause inhibition of NCp7-faciltated annealing. In Fig. 3B, the 1-nt RT extension products of trna 3 are resolved by using 6% 1D PAGE containing 7 M urea. Normalizing values to that obtained for the 1-nt extension from trna 3 annealed by NCp7 in the absence of A3G, we see that the 1-nt extension from trna 3 annealed by Gag p6 is ca. 27% of that achieved by NCp7-facilitated annealing. The presence of A3G in the NCp7 annealing mixture reduces 1-nt extension to ca. 22% but has no effect upon initiation when added to a Gag p6 annealing mixture. These results show the same pattern as those obtained in Fig. 1D using RNA isolated from Pr( )Vif( ) and Pr( ) Vif( ) virions, in the presence or absence of A3G. The 6-nt extension data shown in Fig. 1C or in Fig. 3A indicate that the reduced 1-nt extension for Gag-annealed trna 3 is due less to the amount of trna 3 annealed and more to its weakened placement on the viral RNA (Fig. 2B and 3B). This is further indicated by the data shown in Fig. 3C, where, using the electrophoretic band shift method to resolve free trna 3 from annealed trna 3, we directly measured the amount of labeled trna 3 annealed by either NCp7 or Gag p6, in the presence or absence of A3G. In our annealing conditions, NCp7, in the absence of A3G, anneals ca. 37% of trna 3 to the viral RNA, and there is a 55% reduction when A3G is present. Gag p6 anneals ca. 84% as much of the trna 3 as is annealed by NCp7, with no change occurring when A3G is also present during annealing. Thus, the data using the electrophoretic band shift method strongly support the 6-nt extension data obtained in both Fig. 1C and 3A on the effects of NCp7, Gag, and A3G on trna 3 annealing. We have previously reported that the ability of A3G to inhibit the initiation of reverse transcription from trna 3 annealed by NCp7 in vitro depends upon the interaction of A3G with NCp7 (21). We therefore investigated whether the failure of A3G to inhibit Gag p6-facilitated trna 3 annealing in vitro resulted from the inability of A3G to interact with Gag. As described previously for measuring the NCp7/A3G interaction in vitro (21), equimolar amounts of either NCp7 or Gag p6 were incubated with A3G, and their ability to be coimmunoprecipitated with anti-a3g (NIH AIDS Research and Reference Reagent Program) was detected on Western blots probed with goat anti-ncp7 (a gift from Louis Henderson, AIDS Vaccine Program). The results, shown in Fig. 3D, demonstrate that both NCp7 and Gag p6 interact efficiently with A3G. NCp7 rescue of Gag-facilitated trna 3 annealing is inhibited by A3G. We have previously shown that transient exposure of BH10P to NCp7 alone does not affect 6-nt extension, i.e., the amount of annealed trna 3 present, but does result in bringing 1 extension to wild-type levels, i.e., altering trna 3 placement on the viral genome from that obtained by Gag to that obtained by NCp7 (11). We have investigated whether this conversion involves reannealing of trna 3 to the viral genomic RNA by determining whether it is sensitive to the presence of A3G, since A3G only inhibits annealing facilitated by NCp7, and not by Gag (Fig. 1C), and this inhibition requires A3G to be present during the annealing process (21). Total viral RNA was isolated from BH10 and BH10P, and the

6 8104 GUO ET AL. J. VIROL. Downloaded from FIG. 3. Effect of A3G on the Gag p6- or NCp7-facilitated annealing of trna 3 to viral RNA in vitro. We determined that 1 pmol of synthetic viral genomic RNA and 1 pmol of purified human placental trna 3 were incubated with 30 pmol of either Gag p6 or NCp7, in the presence of A3G or its absence (A3G replaced with BSA). (A and B) The resultin trna 3 /viral RNA complex was then used as a source of primer trna 3 /template viral genomic RNA in an in vitro reverse transcription system containing HIV-1 RT and deoxynucleotides, to produce either a 6-nt or a 1-nt extension of trna 3, as described in the legend to Fig. 1. Shown are 1D PAGE patterns of trna 3 extended by either 6 (A) or 1 (B) nt, with quantitation of the results, relative to that of NCp7-facilitated annealing in the absence of A3G, shown below each lane. (C) The same annealing conditions as used for experiments in panels A and B were used with labeled trna 3, and annealed versus free trna 3 were resolved by native 1D PAGE. The fraction of total trna 3 that was annealed is shown below each lane. (D) The interaction of 30 pmol of Gag p6 or NCp7 with A3G. Gag p6 or NCp7 was incubated with 1 pmol of A3G, and the ability of Gag p6 or NCp7 to be coimmunoprecipitated with A3G, using anti-a3g, was detected by Western blots probed with anti-ncp7, as described in the text. The top two panels are Western blots of the reaction prior to immunoprecipitation, probed with anti-a3g or anti-ncp7, respectively. The lower panel is a Western blot of the anti-a3g immunoprecipitate from each reaction, probed with anti-ncp7. 6-nt and 1-nt experiments, and Western blots were repeated twice, while the electrophoretic band shift experiments were done three times. on January 3, 2019 by guest RNAs were transiently exposed to BSA alone, or to A3G in the presence of either BSA, Gag p6, or NCp7. The RNAs were then deproteinized and used in the in vitro reverse transcription system under conditions that extend the annealed trna 3 primer by 6 nt. 1D PAGE results and their graphic presentation of the amount of product made relative to BH10 RNA exposed only to BSA are shown in Fig. 4. The left side of the figure shows that once trna 3 is annealed by NCp7 in Pr( )Vif( ) virions, exposure to A3G, in the absence or presence of NCp7 or Gag p6, has little effect upon the initiation of reverse transcription. On the other hand, as shown on the right side of the panel, trna 3 annealed by Gag in Pr( )Vif( ) virions has a 50% reduction of initiation by A3G when in the presence of NCp7, relative to that obtained with BSA and A3G. Since A3G only reduces annealing by NCp7 during the process of annealing, and not after annealing has been accomplished (21), these results suggest that trna 3 annealed by Gag can be displaced by, and reannealed by, NCp7, and allows for the possibility that in Pr( )Vif( ) viruses, annealing may be a two-step process, initially facilitated by Gag and then by NCp7. DISCUSSION In this study, the ability of annealed trna 3 to initiate reverse transcription is studied using two reaction conditions that will allow either a 6-nt extension or a 1-nt extension of annealed trna 3. Measurements of the 6-nt extension and the 1-nt extension reveal the amount of trna 3 annealed

7 VOL. 83, 2009 Gag AND MATURE NUCLEOCAPSID IN trna ANNEALING IN HIV FIG. 4. Ability of A3G to inhibit initiation of reverse transcription from trna 3 annealed in Pr( )Vif( ) or Pr( )Vif( ) viruses, after transient exposure of the annealed complex to A3G in the presence of either BSA, NCp7, or Gag p6. Total viral RNA from BH10 or BH10P was transiently exposed to A3G in the presence of either BSA, NCp7, or Gag p6. After an additional deproteinization, the trna 3 /viral RNA complex was used as a source of primer trna 3 /template viral genomic RNA in an in vitro reverse transcription system containing HIV-1 RT and deoxynucleotides so as to measure 6-nt priming. The upper panel shows 1D PAGE patterns of trna 3 extended by 6 nt, and the lower panel shows quantitation of the results, relative to that of BH10 viral RNA transiently exposed to BSA alone. Experiments were performed twice. and the ability of this annealed trna 3 to initiate reverse transcription, respectively. In the conditions for 6-nt initiation, the concentrations of all dntps (including the [ - 32 P]GTP used) are not limiting for the 6-nt extension, while we have shown that the use of 0.16 M dctp is insufficient for obtaining the maximum 1-nt extension of trna 3 (11). We have interpreted changes in 6-nt initiation resulting from either the absence of protease activity or the presence of A3G as reflecting changes in the amount of trna 3 annealed. This view is supported by additional evidence. For example, the in vitro data using the electrophoretic band shift method to separate free from annealed trna 3 (Fig. 3C) supports the 6-nt extension differences between Pr( )Vif( ) and Pr( )Vif( ) viruses in Fig. 2C by demonstrating that the amount of trna 3 annealed by Gag p6 is only slightly lower than that annealed by NCp7. Similarly, the 60% decrease in 6-nt extension that we observe when A3G is present in Pr( )Vif( ) virions (Fig. 1C) is almost identical to the 58% decrease in the PBS occupancy measured in the same viral RNAs (Fig. 2B). In comparing the initiation of reverse transcription in Pr( )Vif( ) versus Pr( )Vif( ) virions or the absence or presence of A3G in Pr( )Vif( ) viruses, 1-nt extensions always show greater differences than found with the 6-nt extensions (Fig. 1C and D). We interpret these greater differences to reflect greater sensitivity of the 1-nt extension to conformational differences of the annealing complex. For example, our interpretation that there is weaker binding of trna 3 in Pr( )Vif( ) viral RNA is supported by the PBS occupancy data (Fig. 2B), showing that trna 3 annealed in a Pr( )Vif( ) environment is more readily displaced. Thus, while the conditions in the 6-nt extension assay, including the high concentrations of dntps, are able to overcome the differences in annealing configurations between Pr( )Vif( ) and Pr( )Vif( ) virions, allowing for more similar initiation of reverse transcription, these same conditions cannot overcome the inhibitory effect of A3G on initiation of reverse transcription in Pr( )Vif( ) virions. We have previously reported that A3G inhibits NCp7-facilitated trna 3 annealing in vitro only when A3G is present during the annealing step and that this inhibition requires an interaction between A3G and NCp7 (21). Since A3G does not inhibit Gag-facilitated trna 3 annealing in Pr( )Vif( ) viruses (Fig. 1C), it is possible that Gag plays no role in the annealing of trna 3 in Pr( )Vif( ) viruses. However, the results in Fig. 4 and those previously reported (11) are consistent with a possible role for Gag in trna 3 annealing in Pr( )Vif( ) viruses. Thus, we have previously shown that transient exposure of viral RNA from BH10P to NCp7 brings annealing to wild-type levels (11), while the results in Fig. 4 show that transient exposure of viral RNA from Pr( )Vif( ) viruses to NCp7 and A3G indicate that A3G can inhibit this rescue. These data suggest that after trna 3 annealing by Gag, NCp7 can displace the trna 3 and reanneal it to the viral RNA, and this reannealing by NCp7 is subject to A3G inhibition. Although there is no direct proof that Gag actually participates in trna 3 annealing in wild-type viruses, an advantage to having Gag participate in this process is that Gag has been shown to have a binding preference for stem-loops in the 5 region of viral RNA near the region where trna 3 binds, a preference not exhibited by mature NCp7 (13). Gag might thus be able to facilitate a nucleation step that brings trna 3 and the largely, if not entirely, single-stranded PBS sequences together, while NCp7 may be able to facilitate, in addition to nucleation steps, other required changes in viral RNA such as denaturation of double-stranded regions in viral RNA (such as the primer activation signal [3, 4]) and in trna 3 (such as disruption of the D/T C loop interaction [24, 46]), that have been reported to be involved in annealing. Other changes in the conformation of viral RNA bound with Gag or NCp7 that might play a role in availability of RNA sequences for annealing with trna 3 have been suggested from the observation that viral RNA isolated from proteasenegative virions is less thermostable than wild-type viral RNA (17). In addition to problems with RNA conformation, one cannot exclude the possibility that proteins other than nucleocapsid may be involved in promoting trna 3 annealing. For example, connection domain sequences in RT have been shown to be required for the annealing of trna 3 in vivo (12), and a protein complex involved in annealing may require a particular configuration that is achieved better with NCp7 than with Gag. A recent study, using permeabilized virions to study reverse transcription, reported that A3G does not affect trna 3 annealing (5). The experiment was performed by using RT-PCR

8 8106 GUO ET AL. J. VIROL. to amplify extended trna 3 present in virions with or without A3G and concluded that the same amount of trna 3 was extended in both viral types. However, reverse transcription in permeabilized viruses is problematic, since reverse transcription is naturally restricted in virions, and the cause(s) of this restriction remain unknown. Even with permeabilization of the envelope to allow access to exogenous dntps, reverse transcription in virions is inefficient and of low processivity, a point not noted by these authors. Other evidence suggests that proviral DNA synthesis probably depends upon the structure and stability of the viral core (reviewed in reference 43). Thus, PCR in permeabilized virions is generally required to see the DNA products and, when radioactive products are seen after a long incubation periods, their resolution using 1D PAGE shows smears, rather than discrete bands, with very little full-length strong-stop minus-strand synthesis (5, 19, 50, 51). In HIV-1, restriction of reverse transcription is not limited by the annealed trna 3 present, since initiation of DNA synthesis from this trna occurs after infection. If only a small fraction of the annealed trna 3 is extended in permeabilized viruses (i.e., 5 to 10%), one would not be able to detect a 50% reduction in annealed trna 3 in virions by comparing the amount of trna 3 extended in virions containing or lacking A3G. These authors also reported that A3G reduced elongation of minusstrand DNA synthesis in permeabilized viruses. Their result differs from another report that showed a lack of effect of A3G on HIV-1 DNA elongation occurring in the cytoplasm of infected cells (37). Perhaps the finding of Mougel at al. (43) is due to the fact that elongation in permeabilized virions is already very impaired (i.e., low processivity of reverse transcription) even in the absence of A3G, and A3G is acting on this impaired system. Another recent report (31) observed that A3G does not inhibit in vitro annealing of trna 3 to viral RNA, and this report is of interest for the following reason. Using an electrophoretic band shift assay to measure the amount of radioactive trna 3 annealed to viral RNA, their reaction conditions were optimized to achieve 100% trna 3 annealing, while our conditions never achieved more than 40 to 50% annealing. However, our in vitro annealing conditions achieved results similar to what we observed studying trna 3 that had been annealed in vivo, i.e., A3G inhibits NCp7-facilitated annealing but not Gag-facilitated annealing. We would conclude from this comparison that conditions in vivo are not optimized for trna 3 annealing and therefore are subject to more regulation by A3G. Supporting this are the facts that (i) the PBS occupancy by trna 3 annealed in vivo to viral RNA is only 67% (Fig. 2B) and (ii) increasing the amount of trna 3 incorporated into virions results in a near doubling of the trna 3 annealed (18). The in vitro reverse transcription system used here with isolated viral RNA as the source of primer trna 3 annealed to viral RNA template has been designed so that the amount of reverse transcription occurring reflects the amount primer trna 3 annealed to the viral RNA and/or the conformation of the annealed complex. Several pieces of data support the assumption that the isolated annealed primer trna 3 /viral RNA complex used here reflects its annealing state achieved in vivo. The trna 3 /genomic RNA complex is thermally stable, i.e., dissociating at temperatures only above 70 C (47), and the free trna 3 present in total viral RNA does not anneal to genomic RNA under reverse transcription conditions, even in the presence of nucleocapsid (11). Second, deproteinized total viral RNA isolated from virions containing wild-type or mutant proteins has revealed different degrees of trna 3 annealing (27), which must reflect differences occurring in the viruses since the total viral RNA used in the reverse transcription reaction no longer contains these viral proteins. An example of this that is presented here are the differences in annealing we find associated with Pr( )Vif( ) and Pr( )Vif( ) virions. Third, although deproteinized RNA is used in this assay, the continued presence of nucleocapsid protein is not required once nucleocapsid-induced effects upon trna 3 annealing have occurred. Thus, the transient exposure to NCp7 of viral RNA from Pr( ) HIV-1 restores trna 3 annealing to that characteristic for Pr( ) viruses (11) (Fig. 4). We have reported that the amount of trna 3 annealing in a viral population is proportional to the amount of viral trna 3 packaged into the virus (18). It is, however, not known whether trna 3 is first annealed to viral RNA prior to, or after, viral budding. The site of viral assembly where the viral components concentrate, i.e., at the cytoplasmic side of the plasma membrane, should also be the site for the selective concentration of RS and trna 3 necessary for annealing. If annealing is first facilitated by Gag, this weak annealing may be even more reason for concentrating trna 3 here. It is therefore possible that the selective packaging into the virion of RS, and possibly trna 3 as well, may reflect their concentration at the site of viral budding and not actually be required for initiating annealing within the virion. Related to this possibility are our unpublished observations concerning trna Asn (unpublished data). trna Asn is also selectively incorporated into HIV-1, although not to the extent of the trna isoacceptors. Its incorporation is dependent upon GagPol but is independent of RS. Asparaginyl-tRNA synthetase (AsnRS) is in the same structural family as RS, and we have found that Gag also binds to AsnRS in the cytoplasm. Nevertheless, AsnRS is not found in the virion, suggesting that its role in concentrating trna Asn for incorporation may be occurring prior to viral budding. ACKNOWLEDGMENTS This study was supported by the Canadian Institutes for Health Research (grants MOP and MOP to L.K.). We thank Matthias Gotte, Rob Gorelick, and Alan Rein for the gift of reagents. REFERENCES 1. Alce, T. M., and W. Popik APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279: Arts, E. J., X. Li, Z. Gu, L. Kleiman, M. A. Parniak, and M. A. Wainberg Comparison of deoxyoligonucleotide and trna(-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269: Beerens, N., and B. Berkhout The trna primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J. Virol. 76: Beerens, N., F. Groot, and B. Berkhout Initiation of HIV-1 reverse transcription is regulated by a primer activation signal. J. Biol. Chem. 276: Bishop, K. N., M. Verma, E. Y. Kim, S. M. Wolinsky, and M. H. Malim APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4:e Bruce, A. G., and O. C. Uhlenbeck Reactions at the termini of trna with T4 RNA ligase. Nucleic Acids Res. 5:

9 VOL. 83, 2009 Gag AND MATURE NUCLEOCAPSID IN trna ANNEALING IN HIV Campbell, S., and A. Rein In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J. Virol. 73: Carteau, S., R. J. Gorelick, and F. D. Bushman Coupled integration of human immunodeficiency virus type 1 cdna ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J. Virol. 73: Cen, S., F. Guo, M. Niu, J. Saadatmand, J. Deflassieux, and L. Kleiman The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279: Cen, S., Y. Huang, A. Khorchid, J. L. Darlix, M. A. Wainberg, and L. Kleiman The role of Pr55 gag in the annealing of trna 3 to human immunodeficiency virus type 1 genomic RNA. J. Virol. 73: Cen, S., A. Khorchid, J. Gabor, L. Rong, M. A. Wainberg, and L. Kleiman The role of Pr55 gag and NCp7 in trna 3 genomic placement and the initiation step of reverse transcription in HIV-1. J. Virol. 74: Cen, S., M. Niu, and L. Kleiman The connection domain in reverse transcriptase facilitates the in vivo annealing of trna 3 to HIV-1 genomic RNA. Retrovirology 1: Clever, J., C. Sassetti, and T. G. Parslow RNA secondary structure and binding site for gag gene products in the 5 packaging signal of human immunodeficiency virus type 1. J. Virol. 69: Crawford, S., and S. P. Goff A deletion mutation in the 5 part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the Gag and Pol polyproteins. J. Virol. 53: De Rocquigny, H., C. Gabus, A. Vincent, M.-C. Fournie-Zaluski, B. Roques, and J.-L. Darlix Viral RNA annealing activities of human immunodeficiency virus type 1 nucleocapsid protein require only peptide domains outside the zinc fingers. Proc. Natl. Acad. Sci. USA 89: Feng, Y. X., S. Campbell, D. Harvin, B. Ehresmann, C. Ehresmann, and A. Rein The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: possible role in dimerization of genomic RNA and placement of trna on the primer binding site. J. Virol. 73: Fu, W., R. J. Gorelick, and A. Rein Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and proteasedefective virions. J. Virol. 68: Gabor, J., S. Cen, H. Javanbakht, M. Niu, and L. Kleiman Effect of altering the trna 3 concentration in human immunodeficiency virus type 1 upon its annealing to viral RNA, GagPol incorporation, and viral infectivity. J. Virol. 76: Goncalves, J., Y. Korin, J. Zack, and D. Gabuzda Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 70: Guo, F., S. Cen, M. Niu, J. Saadatmand, and L. Kleiman The inhibition of trna 3 -primed reverse transcription by human APOBEC3G during HIV-1 replication. J. Virol. 80: Guo, F., S. Cen, M. Niu, Y. Yang, R. J. Gorelick, and L. Kleiman The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits trna3 annealing to viral RNA. J. Virol. 81: Guo, J., T. Wu, B. F. Kane, D. G. Johnson, L. E. Henderson, R. J. Gorelick, and J. G. Levin Subtle alterations of the native zinc finger structures have dramatic effects on the nucleic acid chaperone activity of human immunodeficiency virus type 1 nucleocapsid protein. J. Virol. 76: Hargittai, M. R., R. J. Gorelick, I. Rouzina, and K. Musier-Forsyth Mechanistic insights into the kinetics of HIV-1 nucleocapsid protein-facilitated trna annealing to the primer binding site. J. Mol. Biol. 337: Hargittai, M. R. S., A. Mangla, R. J. Gorelick, and K. Musier-Forsyth HIV-1 nucleocapsid protein zinc finger structures induce trna 3 tertiary structural changes, but are not critical for primer/template annealing. J. Mol. Biol. 312: Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen- Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim DNA deamination mediates innate immunity to retroviral infection. Cell 113: Henriet, S., L. Sinck, G. Bec, R. J. Gorelick, R. Marquet, and J. C. Paillart Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res. 35: Huang, Y., A. Khorchid, J. Wang, M. A. Parniak, J. Darlix, M. A. Wainberg, and L. Kleiman Effect of mutations in nucleocapsid protein (NCp7) upon Pr160 gag-pol and trna incorporation into HIV-1. J. Virol. 71: Huang, Y., J. Mak, Q. Cao, Z. Li, M. A. Wainberg, and L. Kleiman Incorporation of excess wild-type and mutant trna 3 into HIV-1. J. Virol. 68: Huang, Y., A. Shalom, Z. Li, J. Wang, J. Mak, M. A. Wainberg, and L. Kleiman Effects of modifying the trna 3 anticodon on the initiation of human immunodeficiency virus type 1 reverse transcription. J. Virol. 70: Huang, Y., J. Wang, A. Shalom, Z. Li, A. Khorchid, M. A. Wainberg, and L. Kleiman Primer trna 3 on the viral genome exists in unextended and two base-extended forms within mature human immunodeficiency virus type 1. J. Virol. 71: Iwatani, Y., D. S. Chan, F. Wang, K. S. Maynard, W. Sugiura, A. M. Gronenborn, I. Rouzina, M. C. Williams, K. Musier-Forsyth, and J. G. Levin Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35: Jiang, M., J. Mak, A. Ladha, E. Cohen, M. Klein, B. Rovinski, and L. Kleiman Identification of trnas incorporated into wild-type and mutant human immunodeficiency virus type 1. J. Virol. 67: Kleiman, L., R. Halwani, and H. Javanbakht The selective packaging and annealing of primer trna 3 in HIV-1. Curr. HIV Res. 2: Lapadat-Tapolsky, M., C. Pernelle, C. Borie, and J.-L. Darlix Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1. Nucleic Acids Res. 23: Lecossier, D., F. Bouchonnet, F. Clavel, and A. J. Hance Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: Li, J., M. J. Potash, and D. J. Volsky Functional domains of APOBEC3G required for antiviral activity. J. Cell Biochem. 92: Li, X. Y., F. Guo, L. Zhang, L. Kleiman, and S. Cen APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282: Luo, K., B. Liu, Z. Xiao, Y. Yu, X. Yu, R. Gorelick, and X. F. Yu Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78: Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: Mangeat, B., P. Turelli, S. Liao, and D. Trono A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279: Mariani, R., D. Chen, B. Schrofelbauer, F. Navarro, R. Konig, B. Bollman, C. Munk, H. Nymark-McMahon, and N. R. Landau Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: Mbisa, J. L., R. Barr, J. A. Thomas, N. Vandegraaff, I. J. Dorweiler, E. S. Svarovskaia, W. L. Brown, L. M. Mansky, R. J. Gorelick, R. S. Harris, A. Engelman, and V. K. Pathak Human immunodeficiency virus type 1 cdnas produced in the presence of APOBEC3G exhibit defects in plusstrand DNA transfer and integration. J. Virol. 81: Mougel, M., L. Houzet, and J. L. Darlix When is it time for reverse transcription to start and go? Retrovirology 6: Schafer, A., H. P. Bogerd, and B. R. Cullen Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328: Stewart, L., G. Schatz, and V. M. Vogt Properties of avian retrovirus particles defective in viral protease. J. Virol. 64: Tisne, C., B. P. Roques, and F. Dardel Heteronuclear NMR studies of the interaction of trna 3 with HIV-1 nucleocapsid protein. J. Mol. Biol. 306: Waters, L. C., and B. C. Mullin Transfer RNA in RNA tumor viruses. Prog. Nucleic Acids Res. Mol. Biol. 20: Yu, X., Y. Yu, B. Liu, K. Luo, W. Kong, P. Mao, and X. F. Yu Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: Zennou, V., D. Perez-Caballero, H. Gottlinger, and P. D. Bieniasz APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78: Zhang, H., G. Dornadula, P. Alur, M. A. Laughlin, and R. J. Pomerantz Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. Proc. Natl. Acad. Sci. USA 93: Zhang, H., G. Dornadula, and R. J. Pomerantz Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenvironments: an important stage for viral infection of nondividing cells. J. Virol. 70: Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L. Gao The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94 98.